#arcus-biosciences
Latest news and interesting information about arcus-biosciences.
Truist Starts Arcus Biosciences at Buy on RCC Potential
Truist Securities initiates Arcus Biosciences with Buy rating and $35 price target, citing casdatifan's potential in renal cell carcinoma and immunology pipeline.
...
